Developing Preclinical Safety Assessment of mRNA-LNP Therapeutics for Solid Tumors
Time: 3:25 pm
day: Conference Agenda
Details:
- Presenting key preclinical safety findings with LNP formulations
- Exploring applications in oncology, with a focus on solid tumors
- Discussing translational considerations for advancing mRNA-LNP therapeutics
